http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010244592-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ebfd716a6d868cec0fdcf2af2480107 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8125 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 |
| filingDate | 2010-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcb348e8b0ff8fc751242583dcf5806e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f363494230b51fa50131905be8f1d1bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e008bc0f3baa8162f627e0bdf9e9030 |
| publicationDate | 2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2010244592-A1 |
| titleOfInvention | Recombinant human alpha1-antitrypsin |
| abstract | The present invention relates recombinant human α1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%.The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and/or treatment of a disease associated with AAT deficiency, and/or a disease involving neutrophil-mediated tissue damage. |
| priorityDate | 2009-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.